Tela Bio Expands Board with Addition of Betty Jo Rocchio

Tela Bio has added Betty Jo Rocchio to its board of directors. The company is a commercial-stage medical technology firm focused on soft-tissue reconstruction solutions. Its OviTex portfolio addresses needs in hernia repair and abdominal wall reconstruction, while its OviTex PRS portfolio focuses on plastic and reconstructive surgery.

TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has announced the addition of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors. The appointment comes as the company continues to expand its leadership and strategic direction. Betty Jo Rocchio, currently the Executive Vice President and Chief Nurse Executive at Advocate Health, brings extensive experience in advancing clinical excellence and supply-chain transformation across major healthcare systems.

Dr. Rocchio is a nationally recognized healthcare leader and one of Modern Healthcare’s 50 Most Influential Clinical Executives. Her background includes roles such as Senior Vice President and Chief Nurse Executive at Mercy and various leadership positions at Mount Carmel Health System in Columbus, Ohio. Most recently, she earned a Doctor of Nursing Practice (DNP) in the Nurse Executive track from The Ohio State University.

"Betty Jo’s deep expertise in aligning clinical priorities with supply-chain strategy will be critical as we continue to drive value for our customers and shareholders," said Antony Koblish, Co-founder and Chief Executive Officer of TELA Bio. "We are thrilled to welcome her to our Board of Directors."

Dr. Rocchio commented, "Throughout my career, I’ve seen the critical role group purchasing organizations play in aligning clinical excellence with financial sustainability. TELA Bio is uniquely positioned to partner with providers and GPOs to deliver solutions that reduce costs while enhancing patient outcomes. I look forward to contributing to this important mission."

TELA Bio also announced the departure of Lisa Colleran, who has served on the Board for five years. Ms. Colleran, CEO of IC Surgical and former CEO of LifeCell Corporation, provided extensive leadership and commercial expertise during her tenure. "On behalf of the Board and the entire TELA Bio team, I want to thank Lisa for her invaluable contributions over the past five years," said Mr. Koblish. "Her insights, perspective, and commitment have been instrumental as we advanced our strategy, expanded our portfolio, and grew our commercial footprint. We are grateful for her service and wish her continued success."

TELA Bio's OviTex portfolio addresses needs in hernia repair and abdominal wall reconstruction, while its OviTex PRS portfolio focuses on plastic and reconstructive surgery. The company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials.